Consultation Tool for Hepatitis B Decision-Making – Free Application from CCO

Clinical Care Options presents a new "Interactive Decision Support Tool" for Hepatitis B consultations to help determine whether and how to treat HBV patients, "Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV" Downloading this tool is FREE but requires that you register with Clinical Care Options website: Source: B

The Week in Review: Jan. 18, 2019 – Jan. 25, 2019

Friday, Jan 25, 2019 News Recap: Using Telemedicine HCV Care Model in Prisons in SPAIN “HCV telemedicine program satisfying, cost-effective in Spanish prison:  A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model. Saturday in Surrey! Visit HepC

Saturday in Surrey! Visit HepCBC booth at January 26th Surrey Health Expo

Come visit HepCBC’s “Liver Wellness” info table at the Surrey Health Expo on Saturday, January 26, 2019 between noon and 5 pm. It is at Surrey City Hall, 13450 – 104 Avenue in Surrey. Please stop by to say hello to our volunteers Dr. Anuradha Dhavan, Dr. Urvashi Beruar, and peer advocate Cheryl Reitz. View poster at: View Hep CBC’s 2 page spread in South Asian Health magazine! The

Patients with chronic HBV die at younger age

Patients with chronic hepatitis B virus infection died an average of 14 years younger and had higher incidences of death from all causes compared with the general U.S. population, according to study results recently published in Clinical Infectious Diseases. “In the United States, about 1,800 death certificates annually list hepatitis B virus (HBV) as an underlying or contributing cause of death,” researchers wrote. “However, accurately quantifying mortal

Serum M2BPGi Reliably Assesses Liver Fibrosis in Chronic Hepatitis B

For patients with chronic hepatitis B virus infection (CHB), serum mac-2-binding protein glycosylation isomer (M2BPGi) is a reliable marker for assessing liver fibrosis, according to results published in Clinical and Translational Gastroenterology. M2BPGi presents a noninvasive alternative to the standard invasive liver biopsy for assessing liver fibrosis in CHB. Furthermore, M2BPGi appears to correlate well with histologic stages of liver fibrosis. Af

HBV Basics

This section is under development In the meantime, here are some resources that you can consult. HBV Pamphlet Foreign Language Pamphlets HBV Punjabi HBV Hindi A_Basic_Guide_to_Hepatitis_B.pdf  

The Week in Review: June 1 – June 8, 2018

Friday, June 8, 2018 News Recap: Canada: New guidelines recommend hepatitis C screening be done for those born between 1945 and 1975. The Canadian Association for the Study of the Liver (CASL), a national group of health-care providers and researchers, published its guidelines on testing and treating hepatitis C in Monday's edition of the CMAJ. Canadians born between 1945 and 1975 – essentially the baby-boom generation – should be tested for the pot...

Findings could lead to treatment of hepatitis B

Researchers at the University of Delaware, working with colleagues at Indiana University, have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide. The discovery, which was published April 27 in the journal eLife, reveals previously unknown details about the capsid, or protein shell, that encloses the virus' genetic blueprint. Scientists believe th

The Week in Review: April 20 – April 27, 2018

Friday, April 27, 2018 News Recap: Warnings: Synthetic cannabinoids and Hepatitis A could be a fatal combination. On April 9, 2018, the Missouri Department of Health and Senior Services (DHSS) issued a news release – “Use of Synthetic Cannabinoids Linked to Severe Bleeding in the US,” informing the public about the national outbreak of bleeding illnesses among those consuming synthetic cannabinoids which appear to have been contaminated with a long-...

Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B

About 1 in 4 people with chronic hepatitis B (HBV) infection who reside in North America have metabolic syndrome, which was also independently associated with higher alanine aminotransferase (ALT) levels over time, according to a new study published in Diabetes Care. Metabolic syndrome is a risk factor for chronic liver disease progression, and aside from being directly associated with nonalcoholic fatty liver disease, metabolic syndrome could influence o